Syed Rizvi, M.D.

Syed Rizvi, M.D.

Former chief medical officeratCaribou Biosciences· In proxies 2022–2023

Pay in FY2023-47% from the year before · Caribou Biosciences stock -8.8% the same year

Syed Rizvi, M.D. was paid $1.3M in FY2023 (Dec), down 47%. Caribou Biosciences stock fell 8.8% that year.

Pay$100 in the stock at the end of FY21 → $38
Pay is from the Summary Compensation Table of each Caribou Biosciences proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Caribou BiosciencesPublic company · 4 yr
    • Former chief medical officer2022 – Present · 4 yrStock in role -97%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?